HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Crispin R Dass Selected Research

pigment epithelium-derived factor

11/2021The increasing role of pigment epithelium-derived factor in metastasis: from biological importance to a promising target.
11/2020Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers.
1/2019Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin.
5/2016Pigment epithelium-derived factor (PEDF) regulates metabolism and insulin secretion from a clonal rat pancreatic beta cell line BRIN-BD11 and mouse islets.
2/2016PEDF attenuates insulin-dependent molecular pathways of glucose homeostasis in skeletal myocytes.
1/2016Pigment epithelium-derived factor stimulates skeletal muscle glycolytic activity through NADPH oxidase-dependent reactive oxygen species production.
11/2014Pigment epithelium-derived factor upregulates collagen I and downregulates matrix metalloproteinase 2 in osteosarcoma cells, and colocalises to collagen I and heat shock protein 47 in fetal and adult bone.
7/2014Pigment epithelium-derived factor as a natural matrix metalloproteinase inhibitor: a comparison with classical matrix metalloproteinase inhibitors used for cancer treatment.
1/2013Regulation of MT1-MMP and MMP-2 by the serpin PEDF: a promising new target for metastatic cancer.
1/2012Efficacy of continuously administered PEDF-derived synthetic peptides against osteosarcoma growth and metastasis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Crispin R Dass Research Topics

Disease

85Neoplasms (Cancer)
04/2022 - 01/2002
37Osteosarcoma (Osteogenic Sarcoma)
01/2019 - 01/2006
24Neoplasm Metastasis (Metastasis)
11/2021 - 01/2007
8Colorectal Neoplasms (Colorectal Cancer)
07/2018 - 09/2012
6Insulin Resistance
12/2020 - 02/2015
6Breast Neoplasms (Breast Cancer)
01/2019 - 08/2003
5Diabetes Mellitus
10/2018 - 09/2016
5Necrosis
06/2016 - 01/2010
4Carcinogenesis
01/2021 - 09/2012
4Bone Neoplasms (Bone Cancer)
01/2019 - 09/2008
4Infections
02/2018 - 07/2002
3Atherosclerosis
04/2022 - 01/2002
3Inflammation (Inflammations)
01/2020 - 07/2002
3Type 1 Diabetes Mellitus (Autoimmune Diabetes)
01/2020 - 03/2017
3Skin Neoplasms (Skin Cancer)
04/2019 - 01/2013
3Melanoma (Melanoma, Malignant)
04/2019 - 05/2004
3Pain (Aches)
02/2018 - 01/2016
3Osteolysis
01/2018 - 12/2007
3Chondrosarcoma
09/2014 - 06/2010
2Type 2 Diabetes Mellitus (MODY)
11/2020 - 01/2020
2Bone Fractures (Bone Fracture)
10/2018 - 09/2014
2Diabetic Retinopathy (Retinopathy, Diabetic)
08/2018 - 09/2014
2Carcinoma (Carcinomatosis)
07/2018 - 10/2017
2Adenocarcinoma
07/2018 - 01/2003
2Obesity
03/2018 - 02/2016
2Heart Failure
01/2018 - 01/2010
2Prostatic Neoplasms (Prostate Cancer)
10/2017 - 06/2010
2Liposarcoma
06/2010 - 08/2008
2Cardiovascular Diseases (Cardiovascular Disease)
08/2004 - 01/2004
1Alzheimer Disease (Alzheimer's Disease)
07/2021
1Thyroid Neoplasms (Thyroid Cancer)
01/2021
1Long Term Adverse Effects
01/2021
1Human Influenza (Influenza)
11/2020

Drug/Important Bio-Agent (IBA)

31Pharmaceutical PreparationsIBA
11/2021 - 01/2007
18Doxorubicin (Adriamycin)FDA LinkGeneric
01/2019 - 03/2008
17pigment epithelium-derived factorIBA
11/2021 - 07/2006
15ChitosanIBA
04/2022 - 07/2007
15Catalytic DNA (Deoxyribozyme)IBA
12/2011 - 08/2003
9Proteins (Proteins, Gene)FDA Link
02/2015 - 01/2004
7Insulin (Novolin)FDA Link
12/2020 - 12/2015
7Liposomes (Liposome)IBA
07/2008 - 01/2002
6Biological ProductsIBA
11/2021 - 12/2009
6EnzymesIBA
04/2019 - 03/2010
6Messenger RNA (mRNA)IBA
12/2011 - 01/2004
5SerpinsIBA
11/2021 - 01/2013
5Caspase 2IBA
01/2019 - 08/2008
5LipidsIBA
05/2016 - 01/2002
5CollagenIBA
11/2014 - 01/2007
5OligonucleotidesIBA
01/2013 - 05/2004
4Glucose (Dextrose)FDA LinkGeneric
12/2020 - 05/2014
4Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2018 - 05/2004
4Peptides (Polypeptides)IBA
01/2018 - 12/2006
4DNA (Deoxyribonucleic Acid)IBA
06/2013 - 07/2002
4A-Form DNA (A-DNA)IBA
01/2012 - 04/2010
4Nucleic AcidsIBA
01/2009 - 05/2002
3Vitamin DFDA LinkGeneric
04/2019 - 01/2013
3Zoledronic Acid (Zometa)FDA Link
01/2019 - 12/2007
3PectinsIBA
07/2018 - 10/2017
3Matrix Metalloproteinase 2 (Gelatinase A)IBA
11/2014 - 01/2013
3Matrix Metalloproteinases (MMPs)IBA
07/2014 - 04/2010
3Small Interfering RNA (siRNA)IBA
06/2010 - 01/2009
3HydrogelsIBA
09/2009 - 03/2008
2Serine Proteinase Inhibitors (Serine Protease Inhibitors)IBA
11/2021 - 07/2014
2Therapeutic UsesIBA
11/2021 - 01/2010
2TabletsIBA
07/2021 - 03/2017
2Biomarkers (Surrogate Marker)IBA
01/2021 - 11/2014
2NitrogenIBA
01/2021 - 01/2018
2Amino AcidsFDA Link
01/2021 - 05/2014
2Reactive Oxygen Species (Oxygen Radicals)IBA
12/2020 - 09/2014
2Bile Acids and Salts (Bile Acids)IBA
01/2020 - 10/2019
2LeptinIBA
10/2018 - 12/2008
2Glycoproteins (Glycoprotein)IBA
05/2016 - 01/2012
2NanogelsIBA
08/2015 - 12/2014
2DextrinsIBA
08/2015 - 12/2014
2Matrix Metalloproteinase 14 (MT1-MMP)IBA
11/2014 - 01/2013
2Netrin-1IBA
03/2014 - 09/2012
2CaspasesIBA
01/2012 - 06/2010
2EpitopesIBA
01/2012 - 12/2007
2Rank-FcIBA
04/2010 - 04/2010
2matrigelIBA
12/2007 - 08/2003
2Plasminogen Activators (Plasminogen Activator)IBA
01/2007 - 01/2005
2Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
01/2007 - 01/2005
2CholesterolIBA
01/2004 - 01/2002
2Transcription Factors (Transcription Factor)IBA
01/2004 - 08/2003
1Biopolymers (Biopolymer)IBA
04/2022
1Dosage Forms (Dosage Form)IBA
07/2021
1CarbonIBA
01/2021
1Glutamine (L-Glutamine)FDA Link
01/2021
1VaccinesIBA
01/2021
1Gonadal Steroid Hormones (Sex Hormones)IBA
11/2020
1Antimalarials (Antimalarial Agents)IBA
11/2020
1Metformin (Glucophage)FDA LinkGeneric
11/2020
1Gliclazide (Diamicron)IBA
01/2020
1Excipients (Suspending Agents)IBA
10/2019
125-Hydroxyvitamin D3 1-alpha-Hydroxylase (25 Hydroxyvitamin D3 1 alpha Hydroxylase)IBA
04/2019

Therapy/Procedure

41Therapeutics
11/2020 - 06/2006
12Drug Therapy (Chemotherapy)
03/2014 - 03/2008
3Oral Administration
10/2018 - 09/2016
3Microspheres (Microsphere)
07/2018 - 03/2008
2Radiotherapy
03/2019 - 01/2009